← Oncology Approval Tracker

FDA DECISION ·

Fotivda

tivozanib · AVEO Pharmaceuticals

FDA approvalNew therapyRenal cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory advanced renal cell carcinoma after two or more prior systemic therapies.

LAMPGEN ANALYSIS

Why it matters

The VEGF receptor inhibitor was approved for later-line renal cell carcinoma.

What research teams should watch

Verify prior systemic treatment lines and document blood pressure monitoring and treatment holds.

PRIMARY RECORDS

Sources